Skip to main content

Table 1 Baseline characteristics of the study population

From: Inhaled iloprost improves gas exchange in patients with COVID-19 and acute respiratory distress syndrome

  Iloprost (n = 23) Control (n = 22)
Demographic variables
 Age, years 62 (53–68) 60 (54–69)
 Male, n (%) 15 (65.2) 17 (77.3)
 Caucasian, n (%) 23 (100) 22 (100)
Anthropometric measures and risk factors
 Smokers, n (%) 8 (34.8) 10 (45.5)
 BMI, kg/m2 31.0 (28.0–34.8) 32.0 (26.5–39.6)
Medical history
 Cardiovascular disease, n (%) 8 (34.8) 9 (40.9)
 Chronic lung disease, n (%) 0 (0) 1 (4.5)
 Diabetes mellitus, n (%) 6 (26.1) 7 (31.8)
 Chronic kidney disease, n (%) 3 (13.0) 1 (4.5)
Clinical variables
 Cough, n (%) 21 (91.3) 21 (95.4)
 Dyspnea, n (%) 21 (91.3) 19 (86.4)
 Fever, n (%) 19 (82.6) 18 (81.8)
 Borg dyspnea scale 6 (5–8) 5 (2–8)
Laboratory tests
 WBC, 109/L 5.9 (5.1–8.8) 6.8 (5.2–8.3)
 C-reactive protein, mg/L 131 (102–190) 128 (89–186)
 D-dimer, µg/mL 2.9 (1.9–3.8) 3.5 (1.9–4.6)
Blood gases
 PaO2, mmHg 65.8 (55.1–78.1) 62.0 (49.0–77.7)
 PaCO2, mmHg 32.0 (29.2–35.0) 28.8 (23.8–32.7)
 SpO2, % 89 (88–90) 90 (87–93)
 PaO2/FiO2, mmHg 131 (120–138) 130 (114–168)
Computed tomography
 CT severity scale, 0/1/2/3/4, n (%) 0 (0)/0 (0)/7 (30.4)/9 (39.1)/7 (30.4) 0 (0)/0 (0)/5 (22.7)/14 (63.6)/3 (13.6)
Medications
 Vasopressors, n (%) 0 (0) 0 (0)
 Corticosteroids, n (%) 15 (65.2) 17 (77.3)
 Hydroxychloroquine, n (%) 21 (91.3) 19 (86.4)
 Azithromycin, n (%) 21 (91.3) 19 (86.4)
Respiratory support
 Supplemental oxygen, n (%) 16 (69.6) 14 (63.6)
 CPAP, n (%) 7 (30.4) 8 (36.4)
  1. Data are expressed as absolute values (%) or median (interquartile range)
  2. BMI body mass index, WBC white blood cells, PaO2 arterial oxygen tension, PaCO2 arterial carbon dioxide tension, SpO2 oxygen saturation, FiO2 fraction of inspired oxygen, CT computed tomography, CPAP continuous positive airway pressure